Patents by Inventor Kathy Miller
Kathy Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939383Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.Type: GrantFiled: August 28, 2020Date of Patent: March 26, 2024Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Charles Kaplan, Alessandro Palumbo, Kathy Miller, Hangil Park, Nerissa Mendoza, Majid Ghoddusi
-
Publication number: 20240043542Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: October 11, 2023Publication date: February 8, 2024Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Patent number: 11814431Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: GrantFiled: March 10, 2020Date of Patent: November 14, 2023Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20230058162Abstract: This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).Type: ApplicationFiled: July 27, 2021Publication date: February 23, 2023Inventors: Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
-
Publication number: 20230013293Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: March 2, 2022Publication date: January 19, 2023Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20220403009Abstract: This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).Type: ApplicationFiled: July 14, 2022Publication date: December 22, 2022Inventors: Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
-
Patent number: 11306144Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: GrantFiled: August 23, 2018Date of Patent: April 19, 2022Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20210079096Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4 The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: August 28, 2020Publication date: March 18, 2021Inventors: Charles KAPLAN, Alessandro PALUMBO, Kathy MILLER, Hangil PARK, Nerissa MENDOZA, Majid GHODDUSI
-
Publication number: 20200255528Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: March 10, 2020Publication date: August 13, 2020Applicant: Five Prime Therapeutics, Inc.Inventors: Charles KAPLAN, Derrick HOUSER, Luis BORGES, Gloria BRATTICH, David BELLOVIN, Felicia KEMP, Majid GHODDUSI, Nels P. NIELSON, Kathy MILLER, Maike SCHMIDT
-
Publication number: 20200129632Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: December 9, 2019Publication date: April 30, 2020Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 10626172Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: May 24, 2018Date of Patent: April 21, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20190194315Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: June 17, 2016Publication date: June 27, 2019Applicant: Novartis AGInventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Publication number: 20190119375Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: ApplicationFiled: May 24, 2018Publication date: April 25, 2019Applicant: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20190085080Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: August 23, 2018Publication date: March 21, 2019Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Patent number: 10117953Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: October 3, 2016Date of Patent: November 6, 2018Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Patent number: 10005836Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.Type: GrantFiled: November 13, 2015Date of Patent: June 26, 2018Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
-
Publication number: 20180125996Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: August 30, 2017Publication date: May 10, 2018Inventors: Tinya ABRAMS, Steven COHEN, Christie P. FANTON, Catrin FINNER, Thomas HUBER, Kathy MILLER, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
-
Patent number: 9789203Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: March 12, 2014Date of Patent: October 17, 2017Assignee: Novartis AGInventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Publication number: 20170035905Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: October 3, 2016Publication date: February 9, 2017Applicant: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Patent number: 9498543Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: March 12, 2014Date of Patent: November 22, 2016Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner